ENVERIC BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
ENVERIC BIOSCIENCES, INC. (ENVB) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $4.79 million as of 2018-12-31, per its 10-K/A filed 2020-08-12.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2020-08-12
- 2018-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $4.79M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2018-12-31 | $4.79M 10-K/A · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |